Osseointegration

Definition. Brånemark defined osseointegration as the "direct structural and functional connection between ordered, living bone and the surface of a load-carrying implant", with no intervening fibrous tissue. At the ultrastructural level that means bone mineral in contact with the titanium oxide layer; clinically it means stable, non-mobile fixation that can withstand functional loading.

History. Per-Ingvar Brånemark first described the phenomenon in 1952, when he observed titanium chambers becoming permanently incorporated into rabbit bone. He coined the term in 1981 and applied the principle to dental implants, which revolutionised implant dentistry and later orthopaedic surgery.

What it needs. A biocompatible material, stable fixation and appropriate healing time. Titanium is the gold standard material because of its oxide layer and biocompatibility; tantalum and hydroxyapatite are also biocompatible. Fixation is mechanical at first, a press-fit at surgery, and biological later, as bone forms on and around the implant. Whether bone or fibrous tissue ends up at the interface is determined by primary stability and the control of micromotion during healing.

Why it matters. Osseointegration gives durable biological fixation to joint replacements, dental implants and bone-anchored prostheses, and it provides stable, load-bearing fixation for decades. Direct bone contact allows physiological load transfer without the interface breaking down. Fibrous fixation is mechanically weak and painful under load and loosens progressively under cyclic loading, so an implant that fails to osseointegrate ends in aseptic loosening and revision surgery.

From the implant surface outward. In successful osseointegration, bone mineral is in direct contact with the oxide layer at the molecular level:

1. Titanium oxide (TiO₂) - a 2-10 nm passivation layer
2. Proteoglycan layer - 20-50 nm of adsorbed proteins, including fibronectin and vitronectin
3. Mineralised bone - directly apposed, with no fibrous tissue
4. Osteocyte network - canaliculi connecting to the implant surface

The oxide layer is what bone contacts. Titanium forms its TiO₂ layer spontaneously, within milliseconds, in air and in body fluids. The layer is 2-10 nm thick, amorphous or crystalline, highly biocompatible and osteoconductive. It is chemically inert and not cytotoxic, prevents corrosion and metal-ion release, and allows direct bone apposition with minimal inflammatory response and no foreign-body rejection.

Its surface chemistry. The oxide surface carries hydroxyl groups (-OH), protein adsorption sites and calcium phosphate precipitation sites. It is negatively charged, which attracts proteins and cells, and its low surface energy keeps the foreign-body response low.

The protein layer. Before any cell arrives, proteins from blood and tissue fluid coat the oxide within seconds: fibronectin (cell adhesion), vitronectin (osteoblast binding), albumin (a passivating protein) and complement proteins. This conditioning layer, not the bare metal, is what osteoblasts actually "see". Cells attach to it in sequence:

1. Proteins adsorb to the TiO₂ surface
2. Osteoblast integrins bind the adsorbed proteins
3. The osteoblast adheres and spreads, and adhesion triggers osteogenic differentiation signals
4. Matrix is deposited and mineralises

The Vroman effect. The composition of the protein layer changes over time through competitive, sequential adsorption. The most abundant and highly mobile proteins, such as albumin and fibrinogen, reach the surface fastest and adsorb first. They are progressively displaced by less abundant but higher-affinity proteins, such as high-molecular-weight kininogen and the cell-adhesive proteins fibronectin and vitronectin, which bind the surface more tightly and are adsorbed to titanium within minutes.

Why the sequence matters. Osteoblast integrins recognise fibronectin and vitronectin in the final conditioning layer, so the Vroman sequence determines whether the surface becomes osteoconductive, supporting osteoblast attachment, spreading and matrix deposition. The surface's chemistry, charge, energy and wettability (e.g. the hydroxylated TiO₂ surface) modulate which proteins ultimately dominate. Bioactive and hydrophilic treatments aim to bias the process toward retaining cell-adhesive proteins and so accelerate early osteoblast attachment. That is the rationale behind hydrophilic and nanotextured implant surfaces, and the reason surface design targets protein adsorption, not just roughness.

Histological zones. The zones of bone around an osseointegrated implant:

• Interface zone, 0-50 μm - newly formed woven bone, high osteocyte density, active remodelling
• Transition zone, 50-500 μm - mixed woven and lamellar bone, maturing gradually
• Host bone, beyond 500 μm - native cortical or cancellous bone of normal architecture

Two routes to the surface. Bone reaches an implant either by forming on the implant itself (contact osteogenesis) or by growing out from the host bed across a gap (distance osteogenesis). Contact osteogenesis is faster and more robust and gives better bone-implant contact, which is why it is preferred and why most modern surface treatments aim to promote it.

Contact osteogenesis. Osteogenic cells migrate to the implant, mesenchymal stem cells differentiate directly on its surface, and osteoblasts deposit bone matrix onto it with no intervening cartilage or fibrous tissue. It depends on biocompatible surface chemistry and is the primary mechanism for cementless implants with rough surfaces. Its requirements:

• A biocompatible material - titanium, tantalum or hydroxyapatite
• Surface roughness of Ra 1-10 μm
• Micromotion under 150 μm
• No bacterial contamination

Its timeline. From haematoma to mature lamellar bone on the implant:

• Days 0-7 - haematoma formation and the inflammatory phase
• Weeks 1-2 - mesenchymal stem cells recruited to the surface
• Weeks 2-4 - osteoblast differentiation and woven bone deposition
• Weeks 4-12 - woven bone remodels to lamellar bone
• Months 3-6 - mature lamellar bone in direct contact with the implant

Distance osteogenesis. Bone formation begins at the host bone surface, and osteoblasts migrate across the gap toward the implant until new bone bridges it, much as a fracture heals across a gap. It occurs around smooth-surfaced implants and in small gaps around press-fit components. It depends on osteoblasts migrating from host bone, so it is slower than contact osteogenesis, and it needs a gap under 500 μm (ideally under 200 μm), stable fixation with no micromotion, adequate vascularity in the gap, and time for the bone to migrate.

• Weeks 0-2 - blood clot fills the gap and angiogenesis begins
• Weeks 2-4 - woven bone forms from the host bed outward
• Weeks 4-8 - bone bridges the gap to reach the implant surface
• Weeks 8-16 - consolidation and remodelling
• Months 4-12 - mature lamellar bone fills the gap

Gap size decides the outcome. The narrower the gap, the more reliably it fills with bone:

• Under 50 μm - direct apposition, optimal
• 50-200 μm - reliable osseointegration
• 200-500 μm - possible, but integration is delayed
• Over 500 μm - fibrous tissue interposes and integration fails

Gaps over 500 μm do not reliably osseointegrate: fibrous tissue forms instead of bone, and fixation is unstable and eventually loosens. The aim at surgery is a tight press-fit, with a gap under 200 μm.

Remodelling for the life of the implant. After initial integration at 3-6 months, bone keeps remodelling according to the mechanical stress it carries (Wolff's law). Density increases where the bone is well loaded and bone resorbs where it is stress-shielded, so the pattern of load transfer determines the bone architecture around the implant. Osseointegration remains a dynamic process throughout the life of the implant:

• Months 6-12 - initial adaptation to loading
• Years 1-5 - progressive remodelling toward a density equilibrium
• Beyond 5 years - a stable bone-implant interface, if loading is appropriate

When adaptation fails. Stress shielding causes proximal bone loss around stiff femoral stems (see Complications). Overload causes peri-implant fracture or bone resorption, and micromotion from inadequate fixation causes late loosening.

Cells and signals. The cellular sequence at the interface:

The growth factors involved:

• BMP-2 and BMP-7 - osteoblast differentiation
• VEGF - angiogenesis, essential for bone formation
• PDGF and TGF-β - mesenchymal stem cell recruitment
• FGF - osteoblast proliferation

Two kinds of stability. Primary stability is mechanical, the press-fit achieved at surgery. Secondary stability is biological, the fixation that bone formation provides over 3-6 months. Primary stability is essential: if it is lost before secondary stability develops, the implant fails.

Micromotion. Micromotion greater than 150 μm at the bone-implant interface prevents osseointegration and promotes fibrous tissue formation instead, which is why absolute stability is required during the healing period. The press-fit is what limits micromotion until secondary biological stability develops.

What sets primary stability. On the implant side, a tapered geometry is better than a straight one, a larger diameter gives more contact and a longer implant more fixation area; thread design matters for screws, as does the surface's coefficient of friction. On the bone side, cortical bone holds better than trabecular and young bone better than osteoporotic, and the fixation site (metaphysis or diaphysis) and the surgical technique (undersizing or oversizing the preparation) both matter. There must be sufficient trabecular and cortical bone for fixation.

Choosing the fixation. Cementless fixation is preferred in younger patients (under 60-65 years) with good bone quality: it allows bone ingrowth and leaves no cement mantle to fail. Cemented fixation is preferred in the elderly, in osteoporotic bone, and when immediate fixation is required without 6-12 weeks of protected weight-bearing.

Optimising the patient. The modifiable risk factors to address before surgery:

• Smoking impairs angiogenesis and osteoblast function and reduces osseointegration success by 10-20%; recommend cessation 4-6 weeks before surgery
• Diabetes - an HbA1c greater than 8% is associated with poorer outcomes; optimise glycaemic control preoperatively, targeting an HbA1c under 7.5% if possible
• Osteoporosis reduces primary stability; consider bisphosphonates, and a longer period of protected weight-bearing may be needed

Medications. Bisphosphonates do not impair osseointegration and may enhance it, so they need not be stopped, and calcium and vitamin D supplements continue; any vitamin D deficiency should be addressed. Anticoagulation follows the VTE protocol. Corticosteroids may impair bone healing and chemotherapy reduces bone formation, so both are avoided if possible in the first 6-12 weeks. Teriparatide, a PTH analogue, may enhance bone formation (off-label).

Biological enhancement. Bone marrow aspirate supplies autologous cells; growth factors such as BMP are not routinely used on implants; and platelet-rich plasma has limited evidence for implants.

The intraoperative goals. The operation has to achieve:

1. Primary stability - a tight press-fit with axial and rotational stability and no visible toggling of the implant
2. Maximum bone-implant contact - accurate reaming and broaching, a minimal gap, and no excessive bone removal; preserve cancellous bone where possible, because excessive reaming gives a poor press-fit
3. A protected interface - no thermal injury, careful handling that does not scratch the surface, and no contamination of the porous surface

Implant choice and position. Size the implant for a tight press-fit, with a rough or porous surface, in titanium or Ti-6Al-4V alloy. Place it in the correct alignment and at the correct depth; malalignment increases stress and loosening.

Press-fit. The prepared cavity is undersized by 0.5-1 mm relative to the implant, creating an interference fit in which the bone is slightly compressed around it. Too tight risks fracture; too loose results in micromotion and failure of osseointegration. Confirm stability before closure, and assess bone quality so that the technique can be adjusted if the bone is osteoporotic.

Cementless femoral stem.

1. Start with the smallest broach and progress by 1-2 sizes until the broach has axial and rotational stability
2. Confirm leg length and offset, and assess stability through the range of motion
3. Insert the implant with axial impaction; a stable stem should require the extraction instrument to remove it
4. The implant should not move with manipulation. If it is unstable, upsize or consider cement

Cementless acetabular cup.

1. Ream with sequential hemispherical reamers to bleeding subchondral bone, the final reamer 1-2 mm undersized to the cup
2. Impact the cup into the prepared acetabulum, targeting 40-45° inclination and 15-25° anteversion
3. Confirm stability: the cup should require the extractor to remove it
4. Screws are optional: they provide additional primary stability, go in the safe zone (posterosuperior quadrant), and may not be required with a good press-fit

Heat. Friction from reaming generates heat, and dead bone at the implant interface cannot participate in osseointegration: it is replaced by fibrous tissue and the implant loosens. This is a common cause of "unexplained" early loosening. Prevent it with cool saline irrigation during reaming, sharp instruments (replace dull reamers), an intermittent technique that pauses to cool, and no excessive force or speed. The risk is highest in dense sclerotic bone at revision surgery, with power reaming without irrigation, and with prolonged reaming by dull instruments.

Handling porous and coated implants. Contamination (fibres, debris) impairs bone contact, and scratching can damage the oxide layer or coating; either kind of surface damage reduces the potential for osseointegration.

• Handle the implant by its smooth, non-porous areas, with the dedicated inserter designed for it
• Keep it in its protective packaging until use, and insert it carefully with controlled impaction
• Never touch the porous surface with gloves or instruments, use metal instruments on it, or let it contact drapes or gowns
• Do not drop or scratch the implant

How integration fails. Any of these failure modes can occur early, as a failure to integrate, or late, as the loss of established integration:

• Aseptic loosening - fibrous encapsulation instead of bone integration; the most common
• Periprosthetic infection - bacteria prevent osseointegration and promote fibrous tissue
• Periprosthetic fracture - disrupts the bone-implant interface
• Stress shielding - bone resorption from unloading, the proximal femur in THA

Aseptic loosening. The most common cause of THA and TKA revision. Its mechanisms are failure of primary stability (micromotion), fibrous encapsulation instead of bone formation, progressive osteolysis from wear debris, and stress shielding with bone resorption. The patient has pain with activity, especially loading, and start-up pain, classic for a loose femoral stem, with symptoms progressing over months to years. The radiographic signs are described under Investigations.

Stress shielding. A stiff implant shields bone from its normal stress, and the bone resorbs by Wolff's law ("use it or lose it"). The proximal femur is most affected in THA: stiff implants such as cobalt-chrome femoral stems transfer load distally and shield the proximal bone, and the effect is worse with stiff, fully coated stems. The Engh classification grades its severity:

• Grade 1 - minimal (cortical thinning only)
• Grade 2 - moderate (calcar rounding, cortical thinning)
• Grade 3 - severe (absent calcar, marked thinning)

Periprosthetic infection. Bacterial biofilm on the implant surface and the inflammatory response destroy bone, and direct bone-implant contact cannot be achieved. The risk factors are diabetes, smoking and obesity, immunosuppression, prolonged operative time and prior surgery at the site. Treatment often requires implant removal with staged revision (spacer, then reimplantation), and osseointegration cannot be achieved until the infection is cleared.

Periprosthetic fracture. The Vancouver classification for THA:

• Type A - trochanteric (A-G, A-L)
• Type B - around or below the stem (B1, B2, B3)
• Type C - well distal to the stem

B1 and B2 differ in the state of osseointegration. A B1 fracture has a well-fixed stem with intact osseointegration and is treated by ORIF with the stable stem preserved, maintaining integration. A B2 fracture combines the fracture with a loose stem and lost osseointegration; the loose stem must be revised, and achieving new integration is challenging.

Loading. Immediate full weight-bearing is now the modern standard for most cementless THA with a good press-fit, excellent bone quality and a standard approach without osteotomies. The evidence supports early mobilisation, and modern cementless implants can often tolerate immediate full loading because an adequate press-fit keeps micromotion below the 150 μm threshold. Protected weight-bearing for 6-12 weeks remains appropriate when primary stability is suboptimal, the bone is osteoporotic, bone graft has been placed around the implant, or the operation is a complex reconstruction or a revision. Progression runs: weeks 0-6 per the surgeon's protocol, weeks 6-12 as tolerated, and full activities usually permitted from 3 months.

Follow-up. The early reviews and annual surveillance:

• 2 weeks - wound check
• 6 weeks - clinical review and radiograph
• 3 months - functional assessment
• Annually - clinical examination for pain, function and stability, and a radiograph for radiolucent lines, osteolysis and implant position

When to review early. New onset pain after a pain-free interval, start-up pain or thigh pain, and signs of infection all need early review.

Activity. Walking (unlimited), swimming, cycling, golf and other low-impact activities are generally permitted after an osseointegrated implant, with return to sedentary work at 2-6 weeks and to physical work at 3-6 months. Caution is advised with running and jumping (high impact), contact sports (fracture risk) and heavy lifting, which should be limited to functional needs. Activity level does not clearly affect long-term survival; higher activity may increase wear, which is less relevant with XLPE, and patient satisfaction is often higher with fewer restrictions.

Cementless hip. AOANJRR 2023 survival for cementless THA with osseointegrated implants:

• 10 years - 95-97%
• 15 years - 92-95%
• 20 years - 85-90%

Against cemented fixation. For THA, cementless fixation is now standard in most patients under 70 years, with equivalent or superior long-term outcomes to cemented fixation. At 15 years the AOANJRR cumulative revision rate is 5.8% for cementless and 6.4% for cemented THA, with hybrid fixation similar to cementless at most time points, and revision for aseptic loosening is less than 5%. By age, the registry finds cementless fixation clearly superior under 55, both excellent with cementless slightly better from 55 to 75, and cemented fixation possibly preferred over 75 because of bone quality. XLPE has dramatically reduced wear-related failure.

What predicts a good hip. Good primary stability at surgery, a porous-coated titanium surface, and adequate liner thickness (XLPE).

Cementless knee. Survival is 95-96% at 10 years and 90-94% at 15. Early studies showed higher loosening with cementless components, and modern designs with trabecular metal show equivalent outcomes; the AOANJRR still finds cemented fixation slightly better at 15 years, with revision rates of 5.8% cemented against 6.9% cementless. Cemented fixation remains the gold standard for TKA, though modern cementless designs are closing the gap, and cementless fixation is used selectively in younger patients and for metaphyseal fixation. For hip and knee alike, the choice depends on patient age, bone quality and surgeon experience.

Bone-anchored prostheses. After transfemoral amputation, implant survival is 90-95% at 5 years, the infection rate at the skin-implant interface 10-20%, and mechanical complications 5-10%, and patient satisfaction is high, better than with a socket. Compared with a socket prosthesis, patients walk better, gain enhanced proprioception (osseoperception), have fewer skin problems and don and doff the limb faster. The limitations are staged surgery (6-12 months), an ongoing risk of infection at the abutment, availability limited to high-volume centres, and the careful patient selection required.

Each requirement for osseointegration has a favourable and an unfavourable form, and a clinical strategy for it. Early overload disrupts healing, so loading is protected until secondary stability develops unless the press-fit allows otherwise.

Global picture. Osseointegration is the biological basis of all cementless fixation. Worldwide, cementless fixation now dominates primary total hip arthroplasty in most high-income registries, while cemented fixation remains the predominant approach for total knee arthroplasty and for hip fracture hemiarthroplasty/THA in older patients. The major national joint registries — NJR (England, Wales, NI), AJRR (USA), AOANJRR (Australia), Swedish (SHAR), Norwegian and NZJR — provide the principal real-world evidence on how different fixation methods and implant surfaces osseointegrate and survive. There is no single global guideline for fixation choice; practice is registry- and evidence-led rather than codified.